{"id":"optimized-treatment-opt","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"OPT works by modulating the body's response to a particular condition, leading to improved outcomes for patients.","oneSentence":"OPT is a treatment that targets the underlying cause of a specific disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:38.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT06856031","phase":"","title":"the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-11-01","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":152},{"nctId":"NCT06785493","phase":"","title":"The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-07-01","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":122},{"nctId":"NCT03897439","phase":"PHASE3","title":"Individualizing Pharmacotherapy for African American Smokers","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2019-05-01","conditions":"Smoking Cessation","enrollment":392},{"nctId":"NCT00667745","phase":"PHASE4","title":"Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2008-04","conditions":"Bipolar Disorder","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":656,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Optimized Treatment (OPT)","genericName":"Optimized Treatment (OPT)","companyName":"Second Affiliated Hospital of Wenzhou Medical University","companyId":"second-affiliated-hospital-of-wenzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPT is a treatment that targets the underlying cause of a specific disease. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}